2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
2
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
5
Ovarian Neoplasms
5
Esophageal Neoplasms
5
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Retinoblastoma
2
Resectable Non-small Cell Lung Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Squamous-Cell Lung Cancer
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Retinal Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Lung Non-Small Cell Carcinoma
1
Recurrence
1
Psoriasis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Oropharyngeal Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
NSCLC
1
Multiple Sclerosis
1
Melanoma
1
Interventions
Carboplatin
26
Etoposide
22
Vincristine
18
Melphalan
14
Filgrastim
14
Topotecan
11
Granulocyte Colony-Stimulating Factor
10
Cyclophosphamide
9
Thiotepa
7
Cryotherapy
7
Peripheral Blood Stem Cell Transplantation
4
Mesna
4
Drug Therapy
4
Busulfan
4
Radiotherapy
3
Ifosfamide
3
Doxorubicin
3
Brachytherapy
3
Watchful Waiting
2
Temozolomide
2
Platinum Compounds
2
Magnetic Resonance Imaging
2
Eye Enucleation
2
Cisplatin
2
Blood Specimen Collection
2
trioctyl phosphine oxide
1
sargramostim
1
racotumomab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Retinoblastoma
×
Platinum Compounds
×
Clear all
NCT04681417
2025-11-28
RETINO 2018
Institut Curie
Phase 2/3
Recruiting
225 enrolled
NCT02866136
2025-11-24
RETINO2011
Institut Curie
Phase 2
Active not recruiting
133 enrolled